will semaglutide compound be banned FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified New Novo Nordisk initiatives support

Mineral Deficiencies and Anemia Risk With GLP-1 Drugs The research also points to mineral depletion, not just vitamin issues

(B) Hemoglobin (Hb)

(2024, February 05)

Key findings from published and presented studies include: In a phase 2 obesity trial, higherdose retatrutide produced average weight loss of around 22.824.2% over 48 weeks in people with obesity. In participants with type 2 diabetes, retatrutide achieved substantial weight loss and marked improvements in blood sugar and cardiometabolic markers, though average percentage weight loss was somewhat lower than in nondiabetic obesity cohorts. Early studies also reported significant reductions in liver fat and visceral adipose tissue, with a high proportion of participants with fatty liver disease showing resolution of hepatic steatosis at higher doses. These results have led several reviews to describe retatrutide as a potential game changer in obesity pharmacotherapy, representing the first GLP1/GIP/glucagon triple agonist with robust human data. Popular coverage has highlighted phase 3 data suggesting average weight losses approaching 29% of body weight in some cohorts (roughly 71 pounds), which is about double typical results with semaglutide over comparable periods

Revascularizations, HbA1c, and body weight were also consistently reduced across subgroups